{"id":"7a66b038-c622-5ec8-8f2c-da229d9fc91b","stable_key":"792249b7-a38d-5f43-afb6-2936818a3fa2:tartrazine-atopic-null","predicate":"no_significant_group_response","statement":"The 26-adult crossover study found no significant cutaneous, respiratory or cardiovascular difference between tartrazine and placebo.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"1747a8a4-a145-5ebc-9e78-12d1b8399553","mechanism_event_label":"The 26-adult crossover study found no significant cutaneous, respiratory or cardiovascular difference between tartrazine and placebo.","subject":{"id":"135b5f4d-0c59-5359-a645-39796e820d42","slug":"tartrazine","display_name":"Tartrazine","entity_type_key":"small_molecule"},"object":{"id":"816ab0c2-4c59-513f-b519-4439a3acdd54","slug":"human-atopic-tartrazine-challenge","display_name":"Cutaneous, respiratory and cardiovascular responses in atopic adults","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"1747a8a4-a145-5ebc-9e78-12d1b8399553","stable_key":"792249b7-a38d-5f43-afb6-2936818a3fa2:tartrazine-atopic-null-event","event_type":"observed_relationship","label":"The 26-adult crossover study found no significant cutaneous, respiratory or cardiovascular difference between tartrazine and placebo.","description":"The 26-adult crossover study found no significant cutaneous, respiratory or cardiovascular difference between tartrazine and placebo.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"135b5f4d-0c59-5359-a645-39796e820d42","slug":"tartrazine","display_name":"Tartrazine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"816ab0c2-4c59-513f-b519-4439a3acdd54","slug":"human-atopic-tartrazine-challenge","display_name":"Cutaneous, respiratory and cardiovascular responses in atopic adults","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Tartrazine 35 mg versus placebo","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"Acute challenge; exact observation period not in abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract; unrecovered method details explicitly retained.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; source-specific experimental curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"26 atopic adults with rhinitis, asthma, urticaria or NSAID-related reactions","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small study with no significant group response does not rule out rare individual intolerance.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Tartrazine food-colorant chapter; nutrient, drug and peptide interactions retain their models and limits.","comparator":null,"unit":null,"notes":"","entity":{"slug":"tartrazine","display_name":"Tartrazine","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"26 atopic adults with rhinitis, asthma, urticaria or NSAID-related reactions","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The 26-adult crossover study found no significant cutaneous, respiratory or cardiovascular difference between tartrazine and placebo.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Safety of ingestion of yellow tartrazine by double-blind placebo controlled challenge in 26 atopic adults. (2010). https://pubmed.ncbi.nlm.nih.gov/20106580/ DOI: 10.1016/j.aller.2009.09.009","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral administration","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Double-blind placebo-controlled crossover challenge","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"fb947984-b293-578f-b79d-d4f4713be41b","evidence_kind":"source_excerpt","locator":"Lines 336-345","start_line":336,"end_line":345,"excerpt":"## tartrazine-atopic-null\nThe 26-adult crossover study found no significant cutaneous, respiratory or cardiovascular difference between tartrazine and placebo.\nModel/species: 26 atopic adults with rhinitis, asthma, urticaria or NSAID-related reactions\nTissue: Double-blind placebo-controlled crossover challenge\nExposure: Tartrazine 35 mg versus placebo\nRoute: Oral administration\nDuration: Acute challenge; exact observation period not in abstract\nLimits: Small study with no significant group response does not rule out rare individual intolerance.\nPrimary reference: Safety of ingestion of yellow tartrazine by double-blind placebo controlled challenge in 26 atopic adults. (2010). https://pubmed.ncbi.nlm.nih.gov/20106580/ DOI: 10.1016/j.aller.2009.09.009\nAccess: Primary PubMed abstract; unrecovered method details explicitly retained.","model_system":"26 atopic adults with rhinitis, asthma, urticaria or NSAID-related reactions","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span, not a publisher quotation; primary citation retained.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d9540941-68b4-5a0d-a5c1-828665a918e2","stable_key":"import-792249b7-a38d-5f43-afb6-2936818a3fa2","title":"Tartrazine: mechanisms, molecular forms and cross-actor connections (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted curation of eighteen primary studies. Study-specific citations, negative findings and limitations retained. Not publisher full text.","file_path":"","sha256":"b83a0113a4b743adc91c24504e488f47e10665386b299c4cb0543da8948f4246","revision_id":"3769070e-6af4-5b02-9d8e-f23c84edba1b","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}